Why Real-Time Kinetics Could Be the Missing Link in AI-Driven Drug Discovery
A new focus on real-time kinetics reflects a growing realization that AI needs better experimental inputs, not just better models. In drug discovery, speed is useful only if it is paired with measurements that capture how compounds actually behave over time.
Drug Discovery News highlights a crucial but often underappreciated issue: AI systems are only as good as the biological data they ingest. In drug discovery, one of the biggest limitations has been the reliance on static or incomplete measurements that miss the dynamic nature of target engagement and compound behavior.
Real-time kinetics offers a way to make AI more useful by giving it richer experimental context. Rather than evaluating compounds on simplified endpoints alone, kinetic data can help distinguish molecules that merely bind from those that bind in ways likely to matter therapeutically. That distinction is especially important when discovery programs must optimize for potency, selectivity, and developability at the same time.
This matters because AI is often portrayed as a substitute for wet-lab complexity, when in practice it usually depends on more sophisticated experimentation. The real innovation is not that AI removes the lab, but that it can help interpret better lab data faster and guide the next round of experiments.
The longer-term impact could be significant. If real-time kinetics becomes a standard part of AI-enabled workflows, it may improve hit quality early and reduce expensive downstream failures. That would make AI less of a discovery novelty and more of a structural advantage in candidate selection.